Literature DB >> 11829519

A deviant immune response to viral proteins and transgene product is generated on subretinal administration of adenovirus and adeno-associated virus.

Vibha Anand1, Bethany Duffy, Zaixin Yang, Nadine S Dejneka, Albert M Maguire, Jean Bennett.   

Abstract

The immune response after ocular exposure to foreign antigens varies substantially from that of a typical systemic response. Anterior chamber associated immune deviation (ACAID) has been well documented. The immune response of the subretinal space has not been studied in as much detail. Here, we characterized the immune response of the subretinal space when it encounters the antigens AdV-GFP and AAV-GFP (recombinant adenovirus or adeno-associated virus, respectively), each delivering the reporter gene encoding green fluorescent protein (GFP). Results indicate that the subretinal space possesses an immune-deviant property similar to ACAID. AdV-elicited immune responses following subretinal injections are significantly reduced compared with systemic responses elicited by intradermal injections of the same virus. Furthermore, subretinal AdV administration results in transduction of retinal pigment epithelial cells (RPE), which are the potential antigen presenting cells of the retina. This subsequently generates a population of immunosuppressive Th2-type, cytokine-secreting, splenic T cells. This response may be advantageous to the development of ocular gene therapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11829519     DOI: 10.1006/mthe.2002.0525

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  26 in total

1.  AAV gene transfer to the retina does not protect retrovirally transduced hepatocytes from the immune response.

Authors:  Marta Bellodi-Privato; Guylène Le Meur; Dominique Aubert; Alexandra Mendes-Madera; Virginie Pichard; Fabienne Rolling; Nicolas Ferry
Journal:  J Mol Med (Berl)       Date:  2004-03-24       Impact factor: 4.599

Review 2.  Gene therapy of inherited retinopathies: a long and successful road from viral vectors to patients.

Authors:  Pasqualina Colella; Alberto Auricchio
Journal:  Hum Gene Ther       Date:  2012-08       Impact factor: 5.695

3.  Absence of systemic immune response to adenovectors after intraocular administration to children with retinoblastoma.

Authors:  Cristhian J Ildefonso; Lingkun Kong; Ann Leen; Samantha J Chai; Veronica Petrochelli; Murali Chintagumpala; Mary Y Hurwitz; Patricia Chévez-Barrios; Richard L Hurwitz
Journal:  Mol Ther       Date:  2010-07-06       Impact factor: 11.454

Review 4.  Gene therapy using adeno-associated virus vectors.

Authors:  Shyam Daya; Kenneth I Berns
Journal:  Clin Microbiol Rev       Date:  2008-10       Impact factor: 26.132

5.  The human rhodopsin kinase promoter in an AAV5 vector confers rod- and cone-specific expression in the primate retina.

Authors:  Shannon E Boye; John J Alexander; Sanford L Boye; Clark D Witherspoon; Kristen J Sandefer; Thomas J Conlon; Kirsten Erger; Jingfen Sun; Renee Ryals; Vince A Chiodo; Mark E Clark; Christopher A Girkin; William W Hauswirth; Paul D Gamlin
Journal:  Hum Gene Ther       Date:  2012-09-20       Impact factor: 5.695

6.  Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer.

Authors:  Federico Mingozzi; Yi-Lin Liu; Eric Dobrzynski; Antje Kaufhold; Jian Hua Liu; YuQin Wang; Valder R Arruda; Katherine A High; Roland W Herzog
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

7.  Differential targeting of feline photoreceptors by recombinant adeno-associated viral vectors: implications for preclinical gene therapy trials.

Authors:  A L Minella; F M Mowat; K L Willett; D Sledge; J T Bartoe; J Bennett; S M Petersen-Jones
Journal:  Gene Ther       Date:  2014-07-24       Impact factor: 5.250

8.  Photoreceptor protection by adeno-associated virus-mediated LEDGF expression in the RCS rat model of retinal degeneration: probing the mechanism.

Authors:  Dorit Raz-Prag; Yong Zeng; Paul A Sieving; Ronald A Bush
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-03-25       Impact factor: 4.799

9.  Ocular immune privilege.

Authors:  A W Taylor
Journal:  Eye (Lond)       Date:  2009-01-09       Impact factor: 3.775

Review 10.  AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer.

Authors:  Helena Costa Verdera; Klaudia Kuranda; Federico Mingozzi
Journal:  Mol Ther       Date:  2020-01-10       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.